20th Aug 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
20th Aug 2024 7:00 am |
RNS |
B7-H3 ADC US FDA Breakthrough Therapy Designation |
16th Aug 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
12th Aug 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
6th Aug 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
2nd Aug 2024 7:00 am |
RNS |
FDA Expands Jemperli Approval |
1st Aug 2024 3:00 pm |
RNS |
Total Voting Rights |
31st Jul 2024 7:00 am |
RNS |
2nd Quarter Results |
29th Jul 2024 8:18 am |
RNS |
Statement: Zantac (ranitidine) litigation |
29th Jul 2024 7:00 am |
RNS |
CHMP positive opinion on Arexvy for 50-59 at risk |
19th Jul 2024 10:36 am |
RNS |
Blenrep EMA Filing Acceptance |
18th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
16th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
15th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
12th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
3rd Jul 2024 7:00 am |
RNS |
GSK and CureVac collaboration restructured |
1st Jul 2024 3:00 pm |
RNS |
Total Voting Rights |
28th Jun 2024 5:37 pm |
RNS |
Statement: Zantac (ranitidine) litigation |
24th Jun 2024 7:05 am |
RNS |
Omjjara approved in Japan for myelofibrosis |
24th Jun 2024 7:00 am |
RNS |
EMA validates Jemperli marketing authorisation |
21st Jun 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
12th Jun 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
11th Jun 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
10th Jun 2024 6:27 pm |
RNS |
Statement: Zantac (ranitidine) litigation |
10th Jun 2024 7:00 am |
RNS |
FDA approves Arexvy for adults 50-59 at risk |
3rd Jun 2024 3:00 pm |
RNS |
Total Voting Rights |
3rd Jun 2024 1:03 pm |
RNS |
Unprecedented results in Jemperli trial continue |
3rd Jun 2024 7:05 am |
RNS |
ASCO positive Blenrep DREAMM-8 trial results |
3rd Jun 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
24th May 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
21st May 2024 7:00 am |
RNS |
Positive phase III asthma results for depemokimab |
20th May 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
17th May 2024 7:00 am |
RNS |
GSK completes sale of shares in Haleon plc |
16th May 2024 4:42 pm |
RNS |
GSK announces intention to sell shares in Haleon |
14th May 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
13th May 2024 3:00 pm |
RNS |
Block listing Interim Review |
8th May 2024 6:21 pm |
RNS |
Result of AGM |
8th May 2024 4:57 pm |
RNS |
Board Committee Change |
3rd May 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
1st May 2024 3:00 pm |
RNS |
Total Voting Rights |